H., Suwaki, N., Tateishi, Y., Nakatsukasa, H., Segawa, T. and Hiramatsu, Y. (2005) The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Molecular Endocrinology 19, 1170–1180.
McKnight, K., Jiang, Y., Hart, Y., Cavey, A., Wroe, S., Blank, M., Shoenfeld, Y., Vincent, A., Palace, J. and Lang, B. (2005) Serum antibodies in epilepsy and seizure-associated disorders. Neurology 65, 1730–1736.
Mealey, K.L., Bentjen, S.A., Gay, J.M. and Cantor, G.H. (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11, 727–733.
Miller, D.S. (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends in Pharmacological Sciences 31, 246–254.
Monteiro, R., Adams, V., Keys, D. and Platt, S.R. (2012) Canine idiopathic epilepsy: prevalence, risk factors and outcome associated with cluster seizures and status epilepticus. Journal of Small Animal Practice 53, 526–533.
Muñana, K.R., Zhang, D. and Patterson, E.E. (2010) Placebo effect in canine epilepsy trials. Journal of Veterinary Internal Medicine 24, 166–170.
Muñana, K.R., Nettifee-Osborne, J.A., Bergman, R.L., Jr and Mealey, K.L. (2012a) Association between ABCB1 genotype and seizure outcome in collies with epilepsy. Journal of Veterinary Internal Medicine 26, 1358–1364.
Muñana, K.R., Thomas, W.B., Inzana, K.D., Nettifee-Osborne, J.A., McLucas, K.J., Olby, N.J., Mariani, C.J. and Early, P.J. (2012b) Evaluation of levetiracetam as adjunctive treatment for refractory canine epilepsy: a randomized, placebo-controlled, crossover trial. Journal of Veterinary Internal Medicine 26, 341–348.
Pakozdy, A., Halasz, P., Klang, A., Bauer, J., Leschnik, M., Tichy, A., Thalhammer, J.G., Lang, B. and Vincent, A. (2013) Suspected Limbic Encephalitis and Seizure in Cats Associated with Voltage-Gated Potassium Channel (VGKC) Complex Antibody. Journal of Veterinary Internal Medicine 27, 212–214.
Pardridge, W.M. (1999) Blood-brain barrier biology and methodology. Journal of Neurovirology 5, 556–569.
Pekcec, A., Unkruer, B., Schlichtiger, J., Soerensen, J., Hartz, A.M., Bauer, B., van Vliet, E.A., Gorter, J.A. and Potschka, H. (2009a) Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. The Journal of Pharmacology and Experimental Therapeutics 330, 939–947.
Pekcec, A., Unkruer, B., Stein, V., Bankstahl, J.P., Soerensen, J., Tipold, A., Baumgartner, W. and Potschka, H. (2009b) Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus. Epilepsy Research 83, 144–151.
Penning, V.A., Connolly, D.J., Gajanayake, I., McMahon, L.A., Luis Fuentes, V., Chandler, K.E. and Volk, H.A. (2009) Seizure-like episodes in 3 cats with intermittent high-grade atrioventricular dysfunction. Journal of Veterinary Internal Medicine 23, 200–205.
Picot, M.C., Baldy-Moulinier, M., Daures, J.P., Dujols, P. and Crespel, A. (2008) The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia 49, 1230–1238.
Placencia, M., Sander, J.W., Shorvon, S.D., Roman, M., Alarcon, F., Bimos, C. and Cascante, S. (1993) Antiepileptic drug treatment in a community health care setting in northern Ecuador: a prospective 12-month assessment. Epilepsy Research 14, 237–244.
Platt, S.R., Adams, V., Garosi, L.S., Abramson, C.J., Penderis, J., De Stefani, A. and Matiasek, L. (2006) Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy. Veterinary Record 159, 881–884.
Podell, M. and Fenner, W.R. (1993) Bromide therapy in refractory canine idiopathic epilepsy. Journal of Veterinary Internal Medicine 7, 318–327.
Potschka, H. (2010) Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia 51, 1333–1347.
Potschka, H. (2012) Role of CNS efflux drug transporters in antiepileptic drug delivery: Overcoming CNS efflux drug transport. Advanced Drug Delivery Reviews 64, 943–952.
Potschka, H., Fedrowitz, M. and Löscher, W. (2002) P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neuroscience Letters 327, 173–176.
Potschka, H., Volk, H.A. and Löscher, W. (2004) Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. Neuroreport 15, 1657–1661.
Rao, V.V., Dahlheimer, J.L., Bardgett, M.E., Snyder, A.Z., Finch, R.A., Sartorelli, A.C. and Piwnica-Worms, D. (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proceedings of the National Academy 96, 3900–3905.
Regesta, G. and Tanganelli, P. (1999) Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Research 34, 109–122.
Remy, S., Gabriel, S., Urban, B.W., Dietrich, D., Lehmann, T.N., Elger, C.E., Heinemann, U. and Beck, H. (2003) A novel mechanism underlying drug resistance in chronic epilepsy. Annals of Neurology 53, 469–479.
Sander, J.W. and Shorvon, S.D. (1996) Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry 61, 433–443.
Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C. and te Riele, H.P. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491–502.
Schinkel, A.H., Wagenaar, E., Mol, C.A. and van Deemter, L. (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 97, 2517–2524.
Schmied, O., Scharf, G., Hilbe, M., Michal, U., Tomsa, K. and Steffen, F. (2008) Magnetic resonance imaging of feline hippocampal necrosis. Veterinary Radiology and Ultrasound 49, 343–349.
Schrickx, J.A. and Fink-Gremmels, J. (2008) Implications of ABC transporters on the disposition of typical veterinary medicinal products. European Journal of Pharmacology 585, 510–519.
Schwartz-Porsche, D. (1986) Epidemiological, clinical and pharmacokinetic studies in spontaneously epileptic dogs and cats. Proceedings of the American College of Veterinary Internal Medicine, pp. 1161–1163.
Schwartz-Porsche, D., Löscher, W. and Frey, H.H. (1985) Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. Journal of Veterinary Pharmacology and Therapeutics 8, 113–119.
Seppala, E.H., Jokinen, T.S., Fukata, M., Fukata, Y., Webster, M.T., Karlsson, E.K., Kilpinen, S.K., Steffen, F., Dietschi, E., Leeb, T., Eklund, R., Zhao, X., Rilstone, J.J., Lindblad-Toh, K., Minassian, B.A. and Lohi, H. (2011) LGI2 truncation causes a remitting focal epilepsy in dogs. PLoS Genetics 7, e1002194.
Shihab, N., Bowen, J. and Volk, H.A. (2011) Behavioral changes in dogs associated with the development of idiopathic epilepsy. Epilepsy and Behavior 21, 160–167.
Shukla, S.J., Sakamuru, S., Huang, R., Moeller, T.A., Shinn, P., Vanleer,
